P. Sajosi

Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments

S. Chadda, J. Winstone, S. Ralston, 2015, Orphanet Journal of Rare Diseases.

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

A. Briggs, P. Sajosi, M. Hux, 2016 .

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland

A. Briggs, B. Woods, J. Eaton, 2017, Journal of medical economics.